Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial

• Published in: The American heart journal Vol. 176; pp. 53 - 62
• Main Authors: Blumenthal, James A., Feger, Bryan J., Smith, Patrick J., Watkins, Lana L., Jiang, Wei, Davidson, Jonathan, Hoffman, Benson M., Ashworth, Megan, Mabe, Stephanie K., Babyak, Michael A., Kraus, William E., Hinderliter, Alan, Sherwood, Andrew
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2016; Elsevier Limited
• Subjects: Adult; Antidepressants; Anxiety; Anxiety - diagnosis; Anxiety - physiopathology; Anxiety - therapy; Biomarkers - analysis; Cardiovascular disease; Citalopram - administration & dosage; Clinical outcomes; Coronary Artery Disease - blood; Coronary Artery Disease - diagnosis; Coronary Artery Disease - psychology; Coronary Artery Disease - therapy; Diagnostic and Statistical Manual of Mental Disorders; Exercise - physiology; Exercise - psychology; Exercise Therapy - methods; Female; Glycated Hemoglobin A - analysis; Heart Rate; Humans; Male; Middle Aged; Monitoring, Physiologic - methods; Mortality; Panic attacks; Psychological Techniques; Quality of life; Serotonin Uptake Inhibitors - administration & dosage; Treatment Outcome
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2016.03.003

Anxiety is highly prevalent among patients with coronary heart disease (CHD), and there is growing evidence that high levels of anxiety are associated with worse prognosis. However, few studies have evaluated the efficacy of treating anxiety in CHD patients for reducing symptoms and improving clinical outcomes. Exercise and selective serotonin reuptake inhibitors have been shown to be effective in treating patients with depression, but have not been studied in cardiac patients with high anxiety. The UNWIND trial is a randomized clinical trial of patients with CHD who are at increased risk for adverse events because of comorbid anxiety. One hundred fifty participants with CHD and elevated anxiety symptoms and/or with a diagnosed anxiety disorder will be randomly assigned to 12 weeks of aerobic exercise (3×/wk, 35 min, 70%-85% VO2peak), escitalopram (5-20 mg qd), or placebo. Before and after 12 weeks of treatment, participants will undergo assessments of anxiety symptoms and CHD biomarkers of risk, including measures of inflammation, lipids, hemoglobin A1c, heart rate variability, and vascular endothelial function. Primary outcomes include post-intervention effects on symptoms of anxiety and CHD biomarkers. Secondary outcomes include clinical outcomes (cardiovascular hospitalizations and all-cause death) and measures of quality of life. The UNWIND trial (ClinicalTrials.gov NCT02516332) will evaluate the efficacy of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for adverse clinical events in anxious CHD patients.